BCI

BCI (CAS No.: 1245792-51-1) is a small-molecule allosteric inhibitor of dual-specificity phosphatases (DUSPs), primarily targeting DUSP6 and DUSP1, key regulators of MAPK/ERK signaling pathways involved in cellular proliferation, differentiation, and stress responses. In cellular systems, BCI exhibits inhibitory activity at low micromolar concentrations, with reported EC50 values of approximately 13.3 μM for DUSP6 and 8.0 μM for DUSP1, while showing minimal activity against DUSP5, indicating a degree of selectivity within the DUSP family. Mechanistically, BCI functions through allosteric modulation rather than direct active-site inhibition, thereby stabilizing the phosphorylated, active forms of MAP kinases and influencing downstream signaling cascades. It has been shown to modulate inflammatory signaling and reduce intracellular reactive oxygen species levels in experimental models, supporting its utility in studies of oxidative stress and inflammation-related pathways. BCI is widely used in biochemical and cell-based assays to investigate phosphatase regulation, MAPK pathway dynamics, and signal transduction mechanisms, as well as in screening platforms for identifying modulators of phosphatase activity. Experimental concentrations and conditions vary depending on the specific cellular context, assay design, and research objectives.